RPTX — Repare Therapeutics Share News
0.000.00%
Last trade - 00:00- $112.94m
- $0.34m
- $53.48m
Brief: Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Brief: Repare Therapeutics Rp-1664 Demonstrated Potent & Selective Inhibition Of Plk4, Synthetic Lethality In Trim37-High Tumor Cells In Preclinical Studies
Brief: Repare Therapeutics - QTRLY Net Loss $18.9 Million Or $0.45 Per Share
Brief: Repare Therapeutics Q3 Net Income USD -18.879 Million
Brief: Repare Therapeutics Inc. Q2 EPS USD -0.28
Repare Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Repare Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Repare Therapeutics Reports Proof Of Concept For Lunresertib In Clinic
Brief: Repare Therapeutics Provides Business Update And Reports First Quarter 2023 Financial Results
Repare Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Repare Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Repare Therapeutics Appoints Susan Molineaux To Its Board Of Directors
Brief: Repare Therapeutics Presents Initial Clinical Data From The Phase 1/2 Tresr And Attacc Trials
Brief: Repare Therapeutics Announces Plenary Oral Presentation At The 2023 Aacr Annual Meeting On Camonsertib And Additional Data Presentations On Rp-6306
Brief: Repare Therapeutics Inc Has Less Than 2% Of Cash With Silicon Valley Bank
Repare Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Repare Therapeutics Provides Business Update And Reports Q4 And FY 2022 Financial Results
Repare Therapeutics Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Repare Therapeutics Receives $1.5 Mln Payment From Ono Pharma